

IL12B Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP10463b

Specification

IL12B Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P29460
Other Accession NP_002178.2

IL12B Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 3593

Other Names

Interleukin-12 subunit beta, IL-12B, Cytotoxic lymphocyte maturation factor 40 kDa subunit, CLMF p40, IL-12 subunit p40, NK cell stimulatory factor chain 2, NKSF2, IL12B, NKSF2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IL12B Antibody (C-term) Blocking Peptide - Protein Information

Name IL12B

Synonyms NKSF2

Function

Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.

Cellular Location

Secreted.

IL12B Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

IL12B Antibody (C-term) Blocking Peptide - Images



IL12B Antibody (C-term) Blocking Peptide - Background

IL12B is a subunit of interleukin 12, a cytokinethat acts on T and natural killer cells, and has a broad array ofbiological activities. Interleukin 12 is a disulfide-linkedheterodimer composed of the 40 kD cytokine receptor like subunitencoded by this gene, and a 35 kD subunit encoded by IL12A. This cytokine is expressed by activated macrophages that serve as an essential inducer of Th1 cells development. This cytokine has beenfound to be important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to an intracellular pathogen. Overexpression of this gene was observed in the central nervous system of patients with multiple sclerosis(MS), suggesting a role of this cytokine in the pathogenesis of the disease. The promoter polymorphism of this gene has been reported to be associated with the severity of atopic and non-atopic asthmain children.

IL12B Antibody (C-term) Blocking Peptide - References

Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Miteva, L.D., et al. Rheumatol. Int. (2010) In press :de Heens, G.L., et al. J. Clin. Periodontol. 37(2):129-136(2010)Sobti, R.C., et al. Folia Biol. (Praha) 56(3):110-115(2010)